73:
310:
are used as inhibitors of fibrinolysis. Their application may be beneficial in patients with hyperfibrinolysis because they arrest bleeding rapidly if the other components of the haemostatic system are not severely affected. This may help to avoid the use of blood products such as fresh frozen plasma
253:
However, acquired disturbance of fibrinolysis (hyperfibrinolysis), is not uncommon. Many trauma patients have an overwhelming activation of tissue factor and thus massive hyperfibrinolysis. Hyperfibrinolysis may occur in other disease states. It could lead to massive bleeding if not diagnosed and
101:
of the blood vessels, such that, after several days (when the bleeding has stopped), the clot is broken down. This occurs because plasminogen became entrapped within the clot when it formed; as it is slowly activated, it breaks down the fibrin mesh. t-PA and urokinase are themselves inhibited by
148:(FDPs). FDPs compete with thrombin, and thus slow down clot formation by preventing the conversion of fibrinogen to fibrin. This effect can be seen in the thrombin clotting time (TCT) test, which is prolonged in a person that has active fibrinolysis.
214:) from plasma and then observing the time required for clot dissolution. A shortened lysis time indicates a hyperfibrinolytic state and bleeding risk. Such results can be seen in peoples with liver disease,
183:. Clinically, the TEM is useful for near real-time measurement of activated fibrinolysis for at-risk patients, such as those experiencing significant blood loss during surgery.
296:
Thrombolysis refers to the dissolution of the thrombus due to various agents while fibrinolysis refers specifically to the agents causing fibrin breakdown in the clot.
2154:
155:, can be measured using antibody-antigen technology. This is more specific than the TCT, and confirms that fibrinolysis has occurred. It is therefore used to indicate
738:
620:"Utilization of catheter-directed thrombolysis in pulmonary embolism and outcome difference between systemic thrombolysis and catheter-directed thrombolysis"
1130:
97:
are the agents that convert plasminogen to the active plasmin, thus allowing fibrinolysis to occur. t-PA is released into the blood slowly by the damaged
1984:
1222:
1314:
87:, in the liver. Although plasminogen cannot cleave fibrin, it still has an affinity for it, and is incorporated into the clot when it is formed.
164:
2098:
999:
179:. In this assay, increased fibrinolysis is assessed by comparing the TEM profile in the absence or presence of the fibrinolysis inhibitor
731:
1125:
1469:
1047:
1042:
559:
485:
107:
103:
1176:
1265:
261:, and plays a role in disease states associated with inflammation. Plasmin, in addition to lysing fibrin clots, also cleaves the
2140:
2079:
1487:
1460:
1200:
1004:
840:
1414:
780:
2147:
1215:
1080:
724:
30:
from growing and becoming problematic. Primary fibrinolysis is a normal body process, while secondary fibrinolysis is the
110:(PAI-1 and PAI-2). In contrast, plasminogen further stimulates plasmin generation by producing more active forms of both
2213:
1698:
1032:
583:
Tieu BH, Holcomb JB, Schreiber MA (May 2007). "Coagulopathy: its pathophysiology and treatment in the injured patient".
199:
111:
90:
2115:
1789:
1509:
52:
cuts the fibrin mesh at various places, leading to the production of circulating fragments that are cleared by other
190:(ELT) assay. The ELT measures fibrinolysis by clotting the euglobulin fraction (primarily the fibrinolytic factors
145:
1871:
1845:
1837:
1120:
171:. Alternatively, a more rapid detection of fibrinolytic activity, especially hyperfibrinolysis, is possible with
1208:
286:
2103:
1452:
1376:
946:
942:
2192:
1980:
1061:
805:
774:
278:
187:
168:
125:
23:
2042:
1621:
1576:
1102:
511:"Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients"
156:
1432:
1112:
1089:
1070:
1052:
747:
242:
disorders of the fibrinolytic system have been documented. Nevertheless, excess levels of PAI and α
219:
203:
133:
117:
1723:
755:
290:
247:
172:
160:
385:
265:
component C3, and fibrin degradation products have some vascular permeability inducing effects.
1885:
1288:
1283:
1967:
1738:
1728:
1718:
1713:
1708:
1683:
1256:
1243:
1235:
1140:
1097:
710:
690:
641:
600:
565:
555:
532:
491:
481:
458:
303:
262:
618:
Patel N, Patel NJ, Agnihotri K, Panaich SS, Thakkar B, Patel A, et al. (December 2015).
1941:
1772:
1733:
1703:
1153:
1148:
680:
672:
631:
592:
522:
448:
299:
2187:
1745:
820:
799:
785:
307:
282:
136:(TAFI), which modifies fibrin to make it more resistant to the tPA-mediated plasminogen.
2109:
1636:
1322:
1231:
1158:
685:
660:
277:(the breakdown of a thrombus), fibrinolytic drugs are used. They are given following a
2207:
2066:
2036:
1626:
1611:
1606:
1567:
1239:
971:
895:
850:
453:
436:
330:
76:
Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.
2056:
2026:
2004:
1999:
1972:
1921:
1900:
1750:
1689:
1645:
1522:
1465:
1404:
1399:
1380:
1278:
1247:
979:
345:
340:
325:
320:
274:
258:
31:
509:
Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS (June 2008).
410:
676:
2177:
2163:
1926:
1854:
1823:
1755:
1656:
1650:
1640:
1543:
1337:
1327:
1022:
957:
928:
910:
885:
875:
830:
764:
335:
289:
to allow blood flow back to the affected part of the brain; and in the event of
211:
98:
84:
42:
2166:
2031:
1948:
1931:
1916:
1895:
1880:
1875:
1818:
1803:
1777:
1767:
1762:
1616:
1585:
1517:
1497:
1475:
1364:
1348:
1344:
1293:
938:
900:
860:
855:
845:
596:
239:
191:
2019:
2014:
1994:
1989:
1936:
1890:
1864:
1859:
1808:
1666:
1589:
1553:
1527:
1492:
1480:
1442:
1437:
1427:
1389:
1359:
1354:
1332:
1298:
1273:
1037:
994:
989:
984:
870:
865:
569:
495:
360:
180:
94:
694:
645:
604:
536:
462:
72:
2132:
1813:
1798:
1631:
1602:
1593:
1581:
1548:
1394:
933:
923:
918:
527:
510:
365:
53:
27:
2084:
2074:
2051:
1849:
1678:
1422:
1185:
1027:
176:
152:
80:
49:
716:
636:
619:
2046:
952:
809:
350:
57:
46:
38:
311:
with its associated risks of infections or anaphylactic reactions.
1308:
794:
789:
355:
227:
226:
deficiency. Similar results are also seen after administration of
215:
195:
71:
61:
659:
Levy JH, Koster A, Quinones QJ, Milling TJ, Key NS (March 2018).
1953:
814:
2136:
1204:
720:
552:
Disorders of hemostasis and thrombosis : a clinical guide
1000:
Protein Z-related protease inhibitor (ZPI) (inhibits FX, FXI)
34:
due to a medicine, a medical disorder, or some other cause.
661:"Antifibrinolytic Therapy and Perioperative Considerations"
257:
The fibrinolytic system is closely linked to control of
132:
inactivate plasmin. Plasmin activity is also reduced by
1005:
Tissue factor pathway inhibitor (TFPI) (inhibits FIII)
186:
Testing of overall fibrinolysis can be measured by a
144:
Plasmin breaks down fibrin into soluble parts called
2065:
1966:
1909:
1836:
1788:
1677:
1665:
1575:
1566:
1536:
1508:
1451:
1413:
1375:
1307:
1264:
1255:
1167:
1139:
1111:
1088:
1079:
1013:
970:
909:
884:
829:
763:
754:
1071:Thrombin-activatable fibrinolysis inhibitor (TAFI)
476:Cotran RS, Kumar V, Collins T, Robbins SL (1999).
1131:Activated protein C–protein C inhibitor (APC–PCI)
713:of the fibrinolytic pathway (site not available)
554:. New York: McGraw-Hill, Medical Pub. Division.
980:Antithrombin (inhibits FII, FIX, FX, FXI, FXII)
16:Process that prevents blood clots from growing
2148:
1216:
732:
8:
134:thrombin-activatable fibrinolysis inhibitor
2155:
2141:
2133:
1674:
1572:
1261:
1223:
1209:
1201:
1085:
760:
739:
725:
717:
175:(TEM) in whole blood, even in patients on
1048:Plasminogen activator inhibitor-2 (PAI-2)
1043:Plasminogen activator inhibitor-1 (PAI-1)
684:
635:
526:
452:
435:Cesarman-Maus G, Hajjar KA (May 2005).
376:
841:High-molecular-weight kininogen (HMWK)
437:"Molecular mechanisms of fibrinolysis"
281:to dissolve the thrombus blocking the
411:"Fibrinolysis - primary or secondary"
246:-antiplasmin have been implicated in
7:
1126:Thrombin–antithrombin complex (TAT)
478:Robbins pathologic basis of disease
384:BSc, Samuel Mckenzie (2019-03-27).
167:and efficacy of treatment in acute
1033:Tissue plasminogen activator (tPA)
990:Protein S (cofactor for protein C)
550:Goodnight SH, Hathaway WE (2001).
250:and various other disease states.
14:
108:plasminogen activator inhibitor-2
104:plasminogen activator inhibitor-1
83:is produced in an inactive form,
1838:Direct thrombin (IIa) inhibitors
1266:Glycoprotein IIb/IIIa inhibitors
454:10.1111/j.1365-2141.2005.05444.x
1461:Thromboxane synthase inhibitors
1121:Prothrombin fragment 1+2 (F1+2)
781:Platelet membrane glycoproteins
985:Protein C (inhibits FV, FVIII)
441:British Journal of Haematology
151:FDPs, and a specific FDP, the
1:
1699:Low-molecular-weight heparin
1510:Phosphodiesterase inhibitors
1423:Acetylsalicylic acid/Aspirin
677:10.1097/ALN.0000000000001997
112:tissue plasminogen activator
91:Tissue plasminogen activator
861:Factor XII (Hageman factor)
775:von Willebrand factor (vWF)
146:fibrin degradation products
45:, is broken down. Its main
2230:
1181:-antiplasmin complex (PAP)
896:Factor III (tissue factor)
624:Catheter Cardiovasc Interv
480:. Philadelphia: Saunders.
306:(ε-aminocaproic acid) and
2173:
2093:
1671:(with some II inhibition)
597:10.1007/s00268-006-0653-9
285:; experimentally after a
1103:β-Thromboglobulin (β-TG)
711:Graphical representation
230:or after severe stress.
1098:Platelet factor 4 (PF4)
995:Protein Z (inhibits FX)
929:Prothrombin (factor II)
386:"What is Fibrinolysis?"
1981:Plasminogen activators
1453:Thromboxane inhibitors
1377:Prostaglandin analogue
1154:Fibrinopeptide B (FpB)
1149:Fibrinopeptide A (FpA)
821:Glycoprotein VI (GPVI)
786:Glycoprotein Ib (GPIb)
254:treated early enough.
77:
2193:Platelet adhesiveness
2043:serine endopeptidases
1577:Vitamin K antagonists
972:Anticoagulant factors
939:Fibrinogen (factor I)
934:Thrombin (factor IIa)
806:Glycoprotein IIb/IIIa
800:Glycoprotein IX (GP9)
767:(platelet activation)
188:euglobulin lysis time
169:myocardial infarction
114:(tPA) and urokinase.
75:
41:clot, the product of
1790:Direct Xa inhibitors
1622:Ethyl biscoumacetate
1488:Receptor antagonists
1159:Fibrin monomers (FM)
1015:Fibrinolytic factors
833:(contact activation)
315:Fibrinolytic enzymes
273:In a process called
157:deep-vein thrombosis
2214:Fibrinolytic system
1433:Carbasalate calcium
1113:Thrombin generation
1090:Platelet activation
1081:Coagulation markers
756:Coagulation factors
748:Coagulation cascade
37:In fibrinolysis, a
2120:Never to phase III
1968:Thrombolytic drugs
1684:glycosaminoglycans
1257:Antiplatelet drugs
1244:antiplatelet drugs
953:Fibrin (factor Ia)
765:Primary hemostasis
528:10.1093/bja/aen083
291:pulmonary embolism
248:metabolic syndrome
173:thromboelastometry
161:pulmonary embolism
78:
32:breakdown of clots
2201:
2200:
2130:
2129:
1962:
1961:
1832:
1831:
1562:
1561:
1198:
1197:
1194:
1193:
1141:Fibrin generation
966:
965:
886:Extrinsic pathway
831:Intrinsic pathway
637:10.1002/ccd.26108
304:aminocaproic acid
300:Antifibrinolytics
263:complement system
2221:
2157:
2150:
2143:
2134:
1942:Drotrecogin alfa
1922:Antithrombin III
1773:Dermatan sulfate
1746:Oligosaccharides
1675:
1573:
1309:ADP receptor/P2Y
1262:
1225:
1218:
1211:
1202:
1086:
761:
741:
734:
727:
718:
699:
698:
688:
656:
650:
649:
639:
615:
609:
608:
580:
574:
573:
547:
541:
540:
530:
506:
500:
499:
473:
467:
466:
456:
432:
426:
425:
423:
421:
406:
400:
399:
397:
396:
381:
2229:
2228:
2224:
2223:
2222:
2220:
2219:
2218:
2204:
2203:
2202:
2197:
2188:Clot retraction
2169:
2161:
2131:
2126:
2125:
2110:Clinical trials
2089:
2061:
1971:
1958:
1905:
1828:
1784:
1687:
1682:
1670:
1661:
1637:1,3-Indandiones
1579:
1558:
1532:
1504:
1447:
1409:
1371:
1323:Thienopyridines
1312:
1303:
1251:
1232:Antithrombotics
1229:
1199:
1190:
1180:
1163:
1135:
1107:
1075:
1065:
1056:
1009:
962:
905:
888:(tissue factor)
887:
880:
832:
825:
766:
750:
745:
707:
702:
658:
657:
653:
617:
616:
612:
582:
581:
577:
562:
549:
548:
544:
508:
507:
503:
488:
475:
474:
470:
434:
433:
429:
419:
417:
408:
407:
403:
394:
392:
383:
382:
378:
374:
317:
308:tranexamic acid
283:coronary artery
271:
245:
236:
234:Role in disease
223:
207:
142:
129:
121:
70:
17:
12:
11:
5:
2227:
2225:
2217:
2216:
2206:
2205:
2199:
2198:
2196:
2195:
2190:
2185:
2180:
2174:
2171:
2170:
2162:
2160:
2159:
2152:
2145:
2137:
2128:
2127:
2124:
2123:
2122:
2121:
2118:
2107:
2101:
2095:
2094:
2091:
2090:
2088:
2087:
2082:
2077:
2071:
2069:
2063:
2062:
2060:
2059:
2054:
2049:
2039:
2034:
2029:
2024:
2023:
2022:
2017:
2009:
2008:
2007:
2002:
1997:
1992:
1977:
1975:
1964:
1963:
1960:
1959:
1957:
1956:
1951:
1946:
1945:
1944:
1934:
1929:
1924:
1919:
1913:
1911:
1907:
1906:
1904:
1903:
1898:
1893:
1888:
1883:
1878:
1869:
1868:
1867:
1862:
1857:
1842:
1840:
1834:
1833:
1830:
1829:
1827:
1826:
1821:
1816:
1811:
1806:
1801:
1795:
1793:
1786:
1785:
1783:
1782:
1781:
1780:
1775:
1770:
1760:
1759:
1758:
1753:
1743:
1742:
1741:
1736:
1731:
1726:
1721:
1716:
1711:
1706:
1695:
1693:
1672:
1663:
1662:
1660:
1659:
1653:
1648:
1643:
1634:
1629:
1624:
1619:
1614:
1609:
1599:
1597:
1570:
1568:Anticoagulants
1564:
1563:
1560:
1559:
1557:
1556:
1551:
1546:
1540:
1538:
1534:
1533:
1531:
1530:
1525:
1520:
1514:
1512:
1506:
1505:
1503:
1502:
1501:
1500:
1495:
1485:
1484:
1483:
1478:
1473:
1457:
1455:
1449:
1448:
1446:
1445:
1440:
1435:
1430:
1425:
1419:
1417:
1415:COX inhibitors
1411:
1410:
1408:
1407:
1402:
1397:
1392:
1386:
1384:
1373:
1372:
1370:
1369:
1368:
1367:
1362:
1357:
1342:
1341:
1340:
1335:
1330:
1319:
1317:
1310:
1305:
1304:
1302:
1301:
1296:
1291:
1286:
1281:
1276:
1270:
1268:
1259:
1253:
1252:
1240:anticoagulants
1230:
1228:
1227:
1220:
1213:
1205:
1196:
1195:
1192:
1191:
1189:
1188:
1183:
1178:
1173:
1171:
1165:
1164:
1162:
1161:
1156:
1151:
1145:
1143:
1137:
1136:
1134:
1133:
1128:
1123:
1117:
1115:
1109:
1108:
1106:
1105:
1100:
1094:
1092:
1083:
1077:
1076:
1074:
1073:
1068:
1066:-Macroglobulin
1063:
1059:
1054:
1050:
1045:
1040:
1035:
1030:
1025:
1019:
1017:
1011:
1010:
1008:
1007:
1002:
997:
992:
987:
982:
976:
974:
968:
967:
964:
963:
961:
960:
955:
950:
936:
931:
926:
921:
915:
913:
911:Common pathway
907:
906:
904:
903:
898:
892:
890:
882:
881:
879:
878:
873:
868:
863:
858:
853:
848:
843:
837:
835:
827:
826:
824:
823:
818:
812:
803:
797:
792:
777:
771:
769:
758:
752:
751:
746:
744:
743:
736:
729:
721:
715:
714:
706:
705:External links
703:
701:
700:
671:(3): 657–670.
665:Anesthesiology
651:
630:(7): 1219–27.
610:
591:(5): 1055–64.
575:
560:
542:
501:
486:
468:
427:
401:
375:
373:
370:
369:
368:
363:
358:
353:
348:
343:
338:
333:
328:
323:
316:
313:
270:
267:
243:
235:
232:
221:
218:deficiency or
205:
141:
138:
130:-macroglobulin
127:
119:
69:
66:
26:that prevents
15:
13:
10:
9:
6:
4:
3:
2:
2226:
2215:
2212:
2211:
2209:
2194:
2191:
2189:
2186:
2184:
2181:
2179:
2176:
2175:
2172:
2168:
2165:
2158:
2153:
2151:
2146:
2144:
2139:
2138:
2135:
2119:
2117:
2114:
2113:
2111:
2108:
2105:
2102:
2100:
2097:
2096:
2092:
2086:
2083:
2081:
2078:
2076:
2073:
2072:
2070:
2068:
2067:Non-medicinal
2064:
2058:
2055:
2053:
2050:
2048:
2044:
2040:
2038:
2037:Streptokinase
2035:
2033:
2030:
2028:
2025:
2021:
2018:
2016:
2013:
2012:
2010:
2006:
2003:
2001:
1998:
1996:
1993:
1991:
1988:
1987:
1986:
1982:
1979:
1978:
1976:
1974:
1973:fibrinolytics
1969:
1965:
1955:
1952:
1950:
1947:
1943:
1940:
1939:
1938:
1935:
1933:
1930:
1928:
1925:
1923:
1920:
1918:
1915:
1914:
1912:
1908:
1902:
1899:
1897:
1894:
1892:
1889:
1887:
1884:
1882:
1879:
1877:
1873:
1870:
1866:
1863:
1861:
1858:
1856:
1853:
1852:
1851:
1847:
1844:
1843:
1841:
1839:
1835:
1825:
1822:
1820:
1817:
1815:
1812:
1810:
1807:
1805:
1802:
1800:
1797:
1796:
1794:
1791:
1787:
1779:
1776:
1774:
1771:
1769:
1766:
1765:
1764:
1761:
1757:
1754:
1752:
1749:
1748:
1747:
1744:
1740:
1737:
1735:
1732:
1730:
1727:
1725:
1722:
1720:
1717:
1715:
1712:
1710:
1707:
1705:
1702:
1701:
1700:
1697:
1696:
1694:
1691:
1685:
1680:
1676:
1673:
1668:
1664:
1658:
1654:
1652:
1649:
1647:
1644:
1642:
1638:
1635:
1633:
1630:
1628:
1627:Phenprocoumon
1625:
1623:
1620:
1618:
1615:
1613:
1612:Coumatetralyl
1610:
1608:
1607:Acenocoumarol
1604:
1601:
1600:
1598:
1595:
1591:
1587:
1583:
1578:
1574:
1571:
1569:
1565:
1555:
1552:
1550:
1547:
1545:
1542:
1541:
1539:
1535:
1529:
1526:
1524:
1521:
1519:
1516:
1515:
1513:
1511:
1507:
1499:
1496:
1494:
1491:
1490:
1489:
1486:
1482:
1479:
1477:
1474:
1471:
1467:
1464:
1463:
1462:
1459:
1458:
1456:
1454:
1450:
1444:
1441:
1439:
1436:
1434:
1431:
1429:
1426:
1424:
1421:
1420:
1418:
1416:
1412:
1406:
1403:
1401:
1398:
1396:
1393:
1391:
1388:
1387:
1385:
1382:
1378:
1374:
1366:
1363:
1361:
1358:
1356:
1353:
1352:
1350:
1346:
1343:
1339:
1336:
1334:
1331:
1329:
1326:
1325:
1324:
1321:
1320:
1318:
1316:
1313:
1306:
1300:
1297:
1295:
1292:
1290:
1287:
1285:
1282:
1280:
1277:
1275:
1272:
1271:
1269:
1267:
1263:
1260:
1258:
1254:
1249:
1245:
1241:
1237:
1236:thrombolytics
1233:
1226:
1221:
1219:
1214:
1212:
1207:
1206:
1203:
1187:
1184:
1182:
1175:
1174:
1172:
1170:
1166:
1160:
1157:
1155:
1152:
1150:
1147:
1146:
1144:
1142:
1138:
1132:
1129:
1127:
1124:
1122:
1119:
1118:
1116:
1114:
1110:
1104:
1101:
1099:
1096:
1095:
1093:
1091:
1087:
1084:
1082:
1078:
1072:
1069:
1067:
1060:
1058:
1051:
1049:
1046:
1044:
1041:
1039:
1036:
1034:
1031:
1029:
1026:
1024:
1021:
1020:
1018:
1016:
1012:
1006:
1003:
1001:
998:
996:
993:
991:
988:
986:
983:
981:
978:
977:
975:
973:
969:
959:
956:
954:
951:
948:
944:
940:
937:
935:
932:
930:
927:
925:
922:
920:
917:
916:
914:
912:
908:
902:
899:
897:
894:
893:
891:
889:
883:
877:
874:
872:
869:
867:
864:
862:
859:
857:
854:
852:
851:Prekallikrein
849:
847:
844:
842:
839:
838:
836:
834:
828:
822:
819:
816:
813:
811:
807:
804:
801:
798:
796:
793:
791:
787:
784:
782:
778:
776:
773:
772:
770:
768:
762:
759:
757:
753:
749:
742:
737:
735:
730:
728:
723:
722:
719:
712:
709:
708:
704:
696:
692:
687:
682:
678:
674:
670:
666:
662:
655:
652:
647:
643:
638:
633:
629:
625:
621:
614:
611:
606:
602:
598:
594:
590:
586:
579:
576:
571:
567:
563:
561:0-07-134834-4
557:
553:
546:
543:
538:
534:
529:
524:
520:
516:
512:
505:
502:
497:
493:
489:
487:0-7216-7335-X
483:
479:
472:
469:
464:
460:
455:
450:
447:(3): 307–21.
446:
442:
438:
431:
428:
416:
412:
405:
402:
391:
387:
380:
377:
371:
367:
364:
362:
359:
357:
354:
352:
349:
347:
344:
342:
339:
337:
334:
332:
331:Streptokinase
329:
327:
324:
322:
319:
318:
314:
312:
309:
305:
301:
297:
294:
292:
288:
284:
280:
276:
268:
266:
264:
260:
255:
251:
249:
241:
233:
231:
229:
225:
217:
213:
209:
201:
197:
193:
189:
184:
182:
178:
174:
170:
166:
162:
158:
154:
149:
147:
139:
137:
135:
131:
123:
115:
113:
109:
105:
100:
96:
92:
88:
86:
82:
74:
67:
65:
63:
59:
55:
51:
48:
44:
40:
35:
33:
29:
25:
21:
2183:Fibrinolysis
2182:
2057:Fibrinolysin
2027:Anistreplase
2005:Desmoteplase
2000:Tenecteplase
1901:Ximelagatran
1751:Fondaparinux
1690:antithrombin
1646:Diphenadione
1523:Dipyridamole
1466:Dipyridamole
1405:Treprostinil
1400:Prostacyclin
1279:Eptifibatide
1186:D-Dimer (DD)
1169:Fibrinolysis
1168:
1057:-Antiplasmin
1014:
779:
668:
664:
654:
627:
623:
613:
588:
585:World J Surg
584:
578:
551:
545:
521:(6): 792–7.
518:
515:Br J Anaesth
514:
504:
477:
471:
444:
440:
430:
418:. Retrieved
414:
404:
393:. Retrieved
390:News-Medical
389:
379:
346:Serrapeptase
341:Lumbrokinase
326:Desmoteplase
321:Anistreplase
298:
295:
279:heart attack
275:thrombolysis
272:
269:Pharmacology
259:inflammation
256:
252:
237:
224:-antiplasmin
208:-antiplasmin
185:
150:
143:
122:-Antiplasmin
116:
89:
79:
36:
20:Fibrinolysis
19:
18:
2178:Coagulation
2164:Coagulation
2106:from market
1927:Defibrotide
1855:Bivalirudin
1824:Rivaroxaban
1763:Heparinoids
1756:Idraparinux
1657:Tioclomarol
1651:Phenindione
1641:Clorindione
1544:Cloricromen
1338:Ticlopidine
1328:Clopidogrel
1023:Plasminogen
958:Factor XIII
876:Factor VIII
415:MedlinePlus
409:Dugdale D.
336:Nattokinase
212:plasminogen
140:Measurement
99:endothelium
93:(t-PA) and
85:plasminogen
43:coagulation
28:blood clots
2167:physiology
2032:Monteplase
1949:Ramatroban
1932:Nafamostat
1917:Abelacimab
1896:Melagatran
1881:Dabigatran
1876:Argatroban
1819:Otamixaban
1804:Betrixaban
1792:("xabans")
1778:Sulodexide
1768:Danaparoid
1739:Tinzaparin
1729:Parnaparin
1724:Nadroparin
1719:Enoxaparin
1714:Dalteparin
1709:Certoparin
1669:inhibitors
1617:Dicoumarol
1518:Cilostazol
1498:Terutroban
1476:Picotamide
1365:Ticagrelor
1349:nucleoside
1345:Nucleotide
1315:inhibitors
1294:Sibrafiban
901:Factor VII
856:Kallikrein
846:Bradykinin
395:2024-05-31
372:References
302:, such as
240:congenital
192:fibrinogen
68:Physiology
56:or by the
2116:Phase III
2104:Withdrawn
2020:Urokinase
2015:Saruplase
1995:Reteplase
1990:Alteplase
1937:Protein C
1891:Inogatran
1886:Efegatran
1872:Univalent
1865:Lepirudin
1860:Desirudin
1809:Darexaban
1734:Reviparin
1704:Bemiparin
1667:Factor Xa
1603:Coumarins
1580:(inhibit
1554:Vorapaxar
1528:Triflusal
1493:Terbogrel
1481:Terbogrel
1470:+ aspirin
1443:Triflusal
1438:Indobufen
1428:Aloxiprin
1390:Beraprost
1360:Elinogrel
1355:Cangrelor
1333:Prasugrel
1299:Tirofiban
1289:Roxifiban
1284:Orbofiban
1274:Abciximab
1177:Plasmin-α
1038:Urokinase
871:Factor IX
866:Factor XI
420:August 7,
361:Bromelain
181:aprotinin
95:urokinase
54:proteases
2208:Category
1846:Bivalent
1814:Edoxaban
1799:Apixaban
1632:Warfarin
1549:Ditazole
1395:Iloprost
1351:analogs
924:Factor V
919:Factor X
695:29200009
646:26308961
605:17426904
570:45485184
537:18440953
496:39465455
463:15842654
366:Honokiol
2085:Oxalate
2075:Citrate
2052:Brinase
1850:Hirudin
1679:Heparin
1655:Other:
1028:Plasmin
686:5811331
177:heparin
153:D-dimer
81:Plasmin
50:plasmin
24:process
2099:WHO-EM
2047:Ancrod
2041:Other
1688:(bind
1681:group/
815:GPIIIa
693:
683:
644:
603:
568:
558:
535:
494:
484:
461:
351:Papain
287:stroke
210:, and
58:kidney
47:enzyme
39:fibrin
1985:r-tPA
1910:Other
1537:Other
810:GPIIb
795:GP1BB
790:GP1BA
356:DNase
228:DDAVP
216:PAI-1
196:PAI-1
62:liver
22:is a
2080:EDTA
2011:UPA
1954:REG1
1381:PGI2
1242:and
691:PMID
642:PMID
601:PMID
566:OCLC
556:ISBN
533:PMID
492:OCLC
482:ISBN
459:PMID
422:2011
238:Few
124:and
106:and
60:and
1586:VII
1248:B01
1246:) (
947:FGG
943:FGA
681:PMC
673:doi
669:128
632:doi
593:doi
523:doi
519:100
449:doi
445:129
200:tPA
165:DIC
2210::
2112::
2045::
1983::
1874::
1848::
1639::
1605::
1592:,
1590:IX
1588:,
1584:,
1582:II
1311:12
1238:,
945:,
689:.
679:.
667:.
663:.
640:.
628:86
626:.
622:.
599:.
589:31
587:.
564:.
531:.
517:.
513:.
490:.
457:.
443:.
439:.
413:.
388:.
293:.
202:,
198:,
194:,
163:,
159:,
64:.
2156:e
2149:t
2142:v
1970:/
1692:)
1686:/
1596:)
1594:X
1472:)
1468:(
1383:)
1379:(
1347:/
1250:)
1234:(
1224:e
1217:t
1210:v
1179:2
1064:2
1062:α
1055:2
1053:α
949:)
941:(
817:)
808:(
802:)
788:(
783::
740:e
733:t
726:v
697:.
675::
648:.
634::
607:.
595::
572:.
539:.
525::
498:.
465:.
451::
424:.
398:.
244:2
222:2
220:α
206:2
204:α
128:2
126:α
120:2
118:α
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
